Publisher Summary The chapter explains how Novo Nordisk produces a yearly Sustainability Report prepared in accordance with Global Reporting Initiative (GRI) guidelines. The report strives to explain Novo Nordisk's approach to doing business and discusses what it is doing to live up to its promise to deliver on the Triple Bottom Line (TBL). The Novo Nordisk Way of Management not only includes a vision, a set of values, and commitments to the TBL, but also the methodology to monitor and ensure that what the management says and hopes is happening and is truly occurring throughout the company. Novo Nordisk is currently focused on four therapeutic areas: diabetes care, hemostasis management, growth hormone therapy, and hormone-replacement therapy. The company is a world leader in diabetes care, with a broad range of products that include pharmaceuticals, injection devices, and needles. Although Novo Nordisk has always been focused on delivering quality products to their consumers around the world, two defining events broadened the company's stakeholder focus and helped mobilize a more institutionalized approach to corporate ethics and responsibility.